Document:

SECURITIES PURCHASE AGREEMENT

 

THIS SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of the date set forth on the signature page hereto, by and
among AVRA Surgical Robotics, Inc., a Delaware corporation (the “Company”) with an address at c/o Stamell &
Schager, LLP, 1 Liberty Plaza 35th Floor, New York, NY 10006, and the purchasers executing a signature page attached hereto (individually,
an "Purchaser" and collectively, the "Purchasers").

 

WITNESSETH:

 

WHEREAS, each of the
Purchasers has invested in and is a stockholder of AVRA Surgical, Inc. (the "Original AVRA") with the intent of
investing in a surgical robotics company (the "Original AVRA Investment"); and

 

WHEREAS, certain affiliates
of the Original AVRA acquired the Company with the intent of establishing a surgical robotics business;

 

WHEREAS, in connection
with satisfying the purpose and intent of the Original AVRA Investment, the Company desires to issue and sell to the Purchasers
and the Purchasers desire, severally and not jointly, to purchase from the Company up to an aggregate of 26,839,754 shares (the
“Shares”) of the common stock, par value $.0001 per share, of the Company (the “Common Stock”)
at a per share purchase price equal to $0.0001 per share (the "Purchase Price")

 

NOW, THEREFORE, in
consideration of the premises, conditions and promises herein contained, the parties hereto agree as follows:

 

1.           PURCHASE
AND SALE OF SHARES

 

1.1           Sale
and Issuance of Shares

 

(a)          Sale
of Shares. Upon the terms and subject to the conditions set forth in this Agreement, in consideration of the Purchase Price
and for the purpose of satisfying the intent of the Original AVRA Investment, the Company agrees to issue and sell to each of the
Purchasers and each Purchaser agrees to purchase from the Company, the number of Shares set forth on the signature page hereto
for the aggregate Purchase Price set forth on each Purchaser's signature page.

 

(b)          Place
of Closing. The completion of the purchase and sale of the Shares hereunder (the “Closing”) shall take place by
electronic communication at such time as the Company and the Purchasers agree, subject to the satisfaction of all conditions herein.

 

(c)          Deliveries.

 

(i)          The
Company shall deliver to each Purchaser a certificate representing the number of Shares purchased by such Purchaser, duly executed
by the Company, within 10 business days after Closing; and

 

(ii)         At
or prior to the Closing, the Purchasers shall deliver to the Company the Purchase Price in immediately available funds to such
account as the Company may designate.

 

(iii)        The
Company and the Purchasers shall deliver this Agreement duly executed at the Closing.

 

    	 

    	 

    

 

 

1.2           Use
of Proceeds. The Company shall use the proceeds of the sale of the Shares for general working
capital purposes.

 

2.           REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY.

 

The Company hereby
represents, warrants and covenants to the Purchasers as follows:

 

2.1           Organization;
Good Standing. The Company has been duly incorporated or organized, is validly existing as a
corporation or other applicable business entity and is in good standing under the laws of the State of Delaware and has the requisite
power to carry on its business as now conducted.

 

2.2           Authorization.
The Company has the requisite power and authority to enter into this Agreement and to carry out its obligations hereunder. The
execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated
hereby have been duly authorized by the board of directors of the Company and no other actions on the part of the Company are necessary
to authorize this Agreement or the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered
by the Company and constitutes a valid and binding agreement of the Company, enforceable against the Company in accordance with
its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement
of creditors' rights generally or by general principles of equity. The Company shall have authorized the issuance of the Shares,
pursuant to the terms and conditions of this Agreement, and, when issued, sold and delivered in accordance with this Agreement
for the consideration described herein, shall be duly authorized and validly issued, are fully paid and nonassessable, and were
issued in accordance with the registration or qualification provisions of any applicable securities laws or pursuant to valid exemptions
therefrom.

 

2.3           Consents.
The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or
other person in connection with the valid execution, delivery and performance by the Company or the offer, sale or issuance of
the Shares other than the filing of a Form D Notice of Exempt Offering of Securities (“Form D”) with the Commission,
if deemed advisable by the Company, and such filings as are required to be made under applicable state securities laws. 

 

2.4           Compliance.
To the knowledge of the Company’s officers and directors, no claim has been filed against the Company alleging a violation
of any applicable laws or regulations of foreign, federal, state and local governments and all agencies thereof. The Company holds
all of the material permits, licenses, certificates or other authorizations of foreign, federal, state or local governmental agencies
required for the conduct of its business as presently conducted.

 

2.5           Questionable
Payments. Neither the Company, nor any employee, agent or representative of the Company, has,
directly or indirectly, made any bribes, kickbacks, illegal payments or illegal political contributions using the Company’s
funds or made any payments from the Company’s funds to any governmental officials for improper purposes or made any illegal
payments from the Company to obtain or retain business.

 

    	- 2 -

    	 

    

 

 

3.           REPRESENTATIONS
AND WARRANTIES OF THE PURCHASERS.

 

Each Purchaser hereby
represents and warrants to the Company, solely as to itself, as follows:

 

3.1           Authorization.
Each Purchaser has full power and authority to enter into this Agreement, to perform its obligations
hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. This Agreement constitutes a valid
and legally binding obligation of such Purchaser, enforceable in accordance with their respective terms except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies.

 

3.2           Investment.
Each Purchaser is acquiring the Shares solely for investment and for the Purchaser’s own
account, not as a nominee or agent, and not with a view to the resale or distribution thereof. The Purchaser
has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part of any of the Shares and
the Purchaser has no plans to enter into any such agreement or arrangement.

 

3.3           Accredited
Purchaser. The Purchaser is an “Accredited Investor” as that term is defined in Rule
501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and
has truthfully and accurately completed the Accredited Investor Questionnaire attached to this Agreement as Exhibit A and
will submit to the Company such further assurances of such status as may be reasonably requested by the Company.
The Purchaser represents to the Company that any information which the undersigned has heretofore
furnished or is furnishing herewith to the Company is complete and accurate and may be relied upon by the Company in determining
the availability of an exemption from registration under Federal and state securities laws in connection with the offering and
sale of the Shares.

 

3.4           Adequate
Information. The
Purchaser and the Purchaser’s attorney, accountant, purchaser representative and/or tax advisor, if any (collectively, the
“Advisors”), have had a reasonable opportunity to ask questions of and receive answers from the Company’s officers
and any other persons authorized by the Company to answer such questions, concerning, among other related matters, this Agreement,
the Shares, and the business, financial condition, results of operations and prospects of the Company and all such questions have
been answered by the Company to the full satisfaction of the Purchaser and its Advisors, if any. The Purchaser also acknowledges
that the Company may repurchase or issue and sell shares of the Common Stock of the Company at a per share purchase price that
may be greater than the Purchase Price paid for the Shares and such Purchaser has had the opportunity to consult with its Advisors
with respect to the tax implications regarding the purchase of the Shares.

 

3.5           Non-Reliance.
In evaluating the suitability of an investment in the Company, the Purchaser has
not relied upon any representation or other information (oral or written) other than as stated in this Agreement or as contained
in documents so furnished to the Purchaser or its Advisors, if any, by the Company in writing. The Purchaser is not relying on
the Company, or any of its respective employees or agents with respect to the legal, tax, economic and related considerations of
an investment in any the Shares and the Purchaser has relied on the advice of, or has consulted with, only its own Advisors.

 

    	- 3 -

    	 

    

 

 

3.6           No
General Solicitation. Each Purchaser is unaware of, is in no way relying on, and did not become
aware of the offering of the Shares through or as a result of, any form of general solicitation or general advertising including,
without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media
or broadcast over television, radio or over the Internet, in connection with the offering and sale of the Shares and is not purchasing
the Shares as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by,
a person not previously known to the Purchaser in connection with investments in securities generally.

 

3.7           Investor
Suitability. The Purchaser understands and agrees that purchase of the Shares is a high risk
investment and the Purchaser is able to afford an investment in a speculative venture having the risks and objectives of the Company
and has adequate means of providing for Purchaser’s current financial needs and foreseeable contingencies and has no need
for liquidity from its investment in the Shares for an indefinite period of time. The Purchaser must bear the substantial economic
risks of the investment in the Shares indefinitely because none of the Shares may be sold, hypothecated or otherwise disposed of
unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from such registration
is available. The investment is a suitable one for the Purchaser. 

 

3.8           Specific
Purpose. Each Purchaser that is an entity represents that it was not formed for the specific
purpose of acquiring the Shares, is duly organized, validly existing and in good standing under the laws of the state of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of any law or its
charter or other organizational documents, such entity has full power and authority to execute and deliver this Agreement and to
carry out the provisions hereof and thereof and to purchase and hold the Shares, the execution and delivery of this Agreement has
been duly authorized by all necessary action, this Agreement has been duly executed and delivered on behalf of such entity and
is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a representative or fiduciary
capacity, represents that it has full power and authority to execute and deliver this Agreement in such capacity and on behalf
of the Purchaser and the Purchaser has full right and power to perform pursuant to this Agreement and make an investment in the
Company, and represents that this Agreement constitutes a legal, valid and binding obligation of the Purchaser. The execution and
delivery of this Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document
to which the Purchaser is a party or by which it is bound.

 

3.9           Brokers
or Finders. Each Purchaser has taken no action which would give rise to any claim by any person
for brokerage commissions, finders’ fees or the like relating to this Agreement or the transactions contemplated hereby.

 

3.10         Restricted
Securities. None of the Shares are registered under the Securities Act of 1933, as amended (the
“Securities Act”), or any state securities laws. The Purchaser acknowledges that the Shares have not
been recommended by any US Federal or State securities commission or regulatory authority and have not confirmed the accuracy
or determined the adequacy of this Agreement. The Purchaser understands that the offering and sale
of the Shares is intended to be exempt from registration under the Securities Act, by virtue of Section 4(2) thereof and, if deemed
advisable by the Company, the provisions of Regulation D promulgated thereunder, based, in part, upon the representations, warranties
and agreements of the Purchaser contained in this Agreement. The Purchaser understands that the Shares may not be sold,
transferred or otherwise disposed of without registration under the Securities Act or an exemption therefrom.

 

    	- 4 -

    	 

    

 

 

3.11         Legend.
The certificates representing the Shares shall be endorsed with the legend in substantially the
form set forth below:

 

THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS,
AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT
THERETO UNDER SUCH ACT AND APPLICABLE LAWS OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS AND
AN OPINION OF COUNSEL TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

4.           MISCELLANEOUS.

 

4.1           Expenses.
The Company and the Purchasers will each pay their own expenses incurred in connection with the
negotiation, preparation, execution and delivery of this Agreement. 

 

4.2           Survival.
 Except as otherwise provided in this Agreement, all representations, warranties, covenants and
agreements contained in this Agreement shall survive the execution and delivery of this Agreement and the Closing. No investigation
by any of the Purchasers shall affect the survival or enforceability of the Company’s representations, warranties, covenants
and agreements contained in this Agreement.

 

4.3           Notices.
All notices and other communications required or permitted under this Agreement shall be deemed
to have been duly given and made if in writing and if served by personal delivery to the party for whom intended (which shall include
delivery by Federal Express or similar internationally nationally-recognized service) to the following address, or such other address
as may be designated in writing hereafter by, such party. All communications will be sent to the Company at c/o Stamell & Schager,
LLP, 1 Liberty Plaza 35th Floor, New York, NY 10006 and to Purchaser at the address(es) set forth on each Purchaser's signature
page or at such other address(es) as the Company or Purchaser may designate by ten (10) days advance written notice to the other
parties to this Agreement. 

 

4.4           Waiver.
No delay on the part of any party hereto with respect to the exercise of any right, power, privilege
or remedy under this Agreement shall operate as a waiver thereof, nor shall any exercise or partial exercise of any such right,
power, privilege or remedy preclude any further exercise thereof or the exercise of any other right, power, privilege or remedy.
No modification or waiver by any party hereto of any provision of this Agreement or consent to any departure by any other party
therefrom, shall be effective other than in the specific instance and for the purpose for which given.

 

4.5           Remedies.
The rights, powers, privileges and remedies hereunder are cumulative and not exclusive of any
other right, power, privilege or remedy the parties hereto would otherwise have.

 

    	- 5 -

    	 

    

 

 

4.6           Entire
Agreement. This Agreement constitute the entire agreement and understanding among the Purchasers
and the Company, and supersede all prior agreements and understandings, relating to the subject matter hereof.

 

4.7           GOVERNING
LAW; VENUE. This Agreement shall be governed by and construed in accordance
with the laws of THE STATE OF New York, without regard to principles of conflicts of law. venue for any legal action hereunder
shall be the state or federal courts located in the STATE OF New YOrk.

 

4.8           Counterparts.
 This Agreement may be executed in counterparts, each of which shall be deemed an original but
all of which together shall constitute one and the same instrument. Facsimile signatures shall bind the parties hereto to the same
extent as original signatures.

 

4.9           Severability.
Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall,
as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining
provisions of this Agreement and without affecting the validity or enforceability of such provision in any other jurisdiction.

 

4.10         Cross
References. References in this Agreement to any section are, unless otherwise specified, to such
section of this Agreement.

 

4.11         Headings.
The various headings of this Agreement are inserted for convenience only and shall not affect
the meaning or interpretation of this Agreement or any provisions hereof.

 

4.12         Amendment
and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any
provision of this Agreement will be effective unless such modification, amendment or waiver is approved in writing by the Company
and the Purchaser. The failure of any party to enforce any of the provisions of this Agreement will in no way be construed as a
waiver of such provisions and will not affect the right of such party thereafter to enforce each and every provision of this Agreement.

 

4.13         Binding
Effect. Except as otherwise provided herein, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties (including transferees
of the Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. 

 

4.14         Construction.
The parties hereto agree that this Agreement is the product of negotiations between sophisticated
parties and individuals, all of whom were represented by separate counsel, and each of whom had an opportunity to participate in,
and did participate in, the drafting of each provision hereof. Accordingly, ambiguities in this Agreement, if any, shall not be
construed strictly or in favor of or against any party hereto but rather shall be given a fair and reasonable construction without
regard to the rule of contra proferentem. As used in this Agreement, the word “including” shall mean “including
without limitation” and the masculine gender shall include the feminine and the neuter gender.

 

[SIGNATURES FOLLOW]

 

    	- 6 -

    	 

    

 

IN WITNESS WHEREOF, the
parties have executed this Agreement as of July 30, 2012.

 

	 	COMPANY:
	 	 
	 	AVRA SURGICAL ROBOTICS, INC.
	 	 
	 	By:	 
	 	 	Name:	Jared B. Stamell
	 	 	Title:	Vice President
	 	 	 	Secretary-Treasurer

 

    	- 7 -

    	 

    

SECURITIES PURCHASE AGREEMENT

PURCHASER SIGNATURE PAGE

 

	Granite Investors Group, Inc.	 
	Purchaser Name (Please print or type.)	 
	 	 
	Signature	 
	Secretary/Treasurer	 
	Capacity in which signed (if other than individual)	 
	 	 
	Dated as of:	July 30 , 2012	 
	 
	Aggregate number of Shares purchased: 22,500,000
	 
	Aggregate Purchase Price: $2,250.00
	 
	Purchaser Address:
	C/O Stamell & Schager, LLP
	1 Liberty Plaza, 35th Floor
	New York, NY 10006

 

    	- 8 -STOCK PURCHASE AGREEMENT

 

This
Purchase Agreement (the "Agreement") is made and entered into as of the 21st day of August, 2012, by and between
AVRA Surgical Robotics, Inc., a Delaware corporation ("AVRA"), and HeartWare, Inc., a Delaware corporation ("HeartWare").
HeartWare and AVRA are sometimes referred to herein as the "Parties."

 

RECITALS

 

		A.	AVRA is in the business of designing, developing, manufacturing and marketing robotics for medical
and other applications.

 

		B.	HeartWare is in the business of designing, manufacturing and marketing medical devices.

	 	 	 
		C.	To facilitate the development and marketing of robotic devices, HeartWare wishes to make an investment
in AVRA, and AVRA wishes to accept such investment and issue equity therefor, on the terms and subject to the conditions set forth
in this Agreement.

 

ACCORDINGLY, HeartWare and AVRA hereby set forth
their agreement as follows:

 

AGREEMENT

 

		Article 1.	Definitions.

 

		1.1.	"Accredited Investor" has the definition set forth in Regulation D promulgated by the
Securities and Exchange Commission.

 

    	 

    	 

    

 

		1.2.	"Affiliate" means, with respect to any specified Person, any other Person who, directly
or indirectly, controls, is controlled by, or is under common control with such Person. For the purposes of this definition, "control"
means the possession, directly or indirectly, of the power to direct the management
and policies of a Person whether through the ownership of voting securities, contract, or otherwise, and the terms "controlled"
and "controlling" have meanings correlative thereto. 

 

		1.3.	"Agreement" means this Stock Purchase Agreement, as it may be duly supplemented or amended
by the parties hereto.

 

		1.5.	"Company Intellectual Property" means all Intellectual Property owned or used by or licensed
to AVRA or the Subsidiaries (whether exclusively, non-exclusively, jointly with another party or otherwise).

 

		1.6.	"Company Products" means any and all robotic devices, prototypes, equipment, tools or
techniques for medical or other applications, including any and all devices, prototypes, equipment, tools or techniques that are
covered by the Company Intellectual Property.

 

		1.4.	"Court Order" means any judgment, order, writ, award or decree of any United States federal,
state or local, or any supra-national or non-U.S., court or tribunal and any award in any arbitration proceeding or any other Governmental
Authority

 

		1.7.	"Derivative Securities" means any securities or rights convertible into, or exercisable
or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.

 

		1.8.	"Governmental Authority" means any federal, state, local, or any non-U.S. government,
governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral body.

 

    	-2-

    	 

    

 

		1.9.	"Intellectual Property" means (i) inventions, whether or not patentable, whether or not
reduced to practice, and whether or not yet made the subject of a pending patent application or applications; patent applications
and patents (including all divisions, continuations, continuations-in-part, reissues, reexaminations, extensions) and all rights
therein and improvements thereto; (ii) trademarks and service marks; (iii) copyrights (registered or otherwise) in both published
and unpublished works; (iv) computer software, including, without limitation, software code (in any form including source code
and executable or object code), databases, data collections, user interfaces, operating systems and specifications, documentation
and other materials related thereto; (v) trade secrets and confidential, technical and business reformation; and(vi) all product
specifications, technical knowledge, procedures, formulae, confidential information, analytical methodology, designs, plans, processes,
methods, and other proprietary information and know-how.

 

		1.10.	"Laws" means any United States federal,
state and local, and any non-U.S., laws, statutes, regulations, rules, codes
or ordinances enacted, adopted, issued or promulgated by any Governmental Authority or common law. 

 

		1.11.	"Lien" means any lien (statutory or other),
claim, charge, security interest, mortgage, deed of trust, pledge, hypothecation, assignment, conditional sale or other title retention
agreement, preference, priority or other security agreement or preferential
arrangement of any kind, and any easement, encroachment, covenant, restriction, right of way, defect in title or other encumbrance
of any kind. 

 

    	-3-

    	 

    

 

		1.12.	"New Securities" means, collectively, equity
securities of AVRA, whether or not currently authorized, as well as rights, options,
or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.

 

		1.13.	"Permitted Liens" means (i)mechanics',
workmen's, warehousemen's, repairmen's and other like Liens arising in the ordinary course of business or deposits to obtain the
release of such Liens; (ii) Liens for Taxes and other governmental charges
and assessments which are not yet due and payable or are being contested in good faith; (iii) purchase money liens incurred in
the ordinary course of business; and (iv) other Liens or imperfections on property which do not adversely affect title to, detract
from the value of, or impair the existing use of, the property affected by such Lien or imperfection. 

 

		1.14.	"Person" means any individual, corporation,
partnership, trust, limited liability company, association or other entity.

 

		1.15.	"Tax" or "Taxes" means (i) any federal, state, local or non-U.S. taxes, including
net income, gross income, gross receipts, excise, property, sales, use, transfer, license, employment, payroll, withholding, franchise,
alternative or add-on minimum, ad valorem, value-added, windfall profit, severance, production, stamp, environmental or any other
tax or similar tax of any kind whatsoever imposed by any Governmental Authority, and further including any interest, penalties
or additions to tax attributable to such assessments; and (ii) any liability for the payment of amounts with respect to payments
of a type described in clause (i) as a result of being a member of an affiliated,
consolidated, combined or unitary group.

 

    	-4-

    	 

    

 

		Article 2.	Purchase of Shares.

 

		2.1.	Subject to the terms and conditions of this Agreement,
on the Closing Date (as defined below), AVRA will sell and issue to HeartWare 329,064 shares of AVRA Common Stock, $0.0001 par
value per share ("Common Stock"), at a purchase price of $ 3.04
per share, for a total purchase price of One Million Dollars ($1,000,000.00) (the "HeartWare Shares"). The HeartWare
Shares shall represent one percent (1%) of the fully diluted equity of AVRA as of the Closing Date. On the Closing Date, AVRA shall
deliver to HeartWare a certificate representing the HeartWare Shares, free and clear of all Liens. 

 

		2.2.	The sale and issuance of the HeartWare Shares shall
take place remotely via the exchange of documents and signatures on the date hereof (the "Closing,
Date") or at such other time and place as HeartWare and AVRA mutually agree in writing. 

 

		2.3.	AVRA will use the proceeds from the sale of the HeartWare Shares for continued development of robotic
technologies.

 

		Article 3.	AVRA's Representations and Warranties. AVRA makes
the following representations and warranties to HeartWare, except as disclosed by AVRA in the disclosure schedule attached as
Exhibit A to this Agreement, dated as of the date of this Agreement and delivered by AVRA to HeartWare simultaneously herewith
(which disclosure schedule shall contain specific references to the sections or subsections to which the disclosures contained
therein relate and an item on such disclosure schedule shall be deemed to qualify only the particular sections or subsections
specified for such item) (the "Disclosure Schedule").

 

    	-5-

    	 

    

 

		3.1.	Organization; Authority. AVRA is a corporation
duly organized, validly existing and in good standing under the Laws of the State of Delaware. AVRA has the requisite corporate
power and authority to carry on its business as currently being conducted. AVRA, either directly or through a Subsidiary, is duly
licensed or qualified to do business as a foreign corporation and is in good standing under the Laws of each other
jurisdiction in which the character or ownership of its or its Subsidiary’s properties or in which the transaction or character
of its or its Subsidiary’s business makes such qualification necessary, except where the failure to be so licensed or qualified
or in good standing would not be material or have an adverse effect on AVRA or its business or operations as currently conducted.
Attached hereto as Exhibits B and C are true and correct copies of AVRA's Certificate of Incorporation and Bylaws as amended in
effect on the date hereof (AVRA's "Charter Documents"). AVRA is not in violation of any provision of AVRA's Charter Documents.
No amendment to any of AVRA's Charter Documents has been approved or proposed since their adoption in the form attached hereto.

 

		3.2.	Subsidiaries. AVRA has no subsidiaries other than as set forth on the Disclosure Schedule
(a "Subsidiary"). Each Subsidiary is duly organized, validly existing and in good standing under the Laws of its jurisdiction
of incorporation, has the requisite corporate power and authority to carry on its business as currently being conducted, is duly
licensed or qualified to do business and is in good standing under the Laws of each other jurisdiction in which the character or
ownership of its properties or in which the transaction or character of its business
makes such qualification necessary, except where the failure to be so licensed or qualified or in good standing would not be material
or have an adverse effect on its business or operations as currently conducted. 

 

    	-6-

    	 

    

 

		3.3.	Capitalization. 

 

		(a)	The authorized capital stock of AVRA consists of one hundred (100) million shares of Common Stock
and ten million (10) shares of Preferred Stock, of which 31,339,754 shares of Common Stock are presently issued and outstanding.
All of the outstanding shares of Common Stock have been duly authorized and validly issued, and are fully paid and non-assessable
and were issued in compliance with all applicable federal and state securities Laws. No shares of AVRA's Common Stock are, or at
any time have been, subject to a right of repurchase. The authorized and issued shares of Common Stock, including the shares issued
pursuant to this Agreement, are not subject to preemptive rights created by statute, AVRA's Charter Documents, or any agreement
to which AVRA is a party or by which AVRA is bound. Except as stated in Exhibit A, AVRA has no other capital stock authorized,
issued or outstanding. Section 3.3(a) of the Disclosure Schedule sets forth the capitalization of AVRA immediately following the
Closing Date including the number of shares of issued and outstanding Common Stock and the holders of more than five percent thereof.

 

    	-7-

    	 

    

 

		(b)	Except as stated in Exhibit A, AVRA has not issued and does not have outstanding any subscription,
warrant, option, convertible security or other right (contingent or otherwise) to purchase or acquire any shares of the Common
Stock or any other class or securities of capital stock, and is not a party to or bound by any contract (other than this Agreement)
providing for the purchase or acquisition of any shares of AVRA's Common Stock or any other class or securities or capital stock.

 

		3.4.	No Conflict; Consents.

 

		(a)	AVRA's execution and delivery of this Agreement and
the consummation of the transactions contemplated hereby, does not and will not (i) conflict with or violate
any provision of AVRA's Charter Documents, (ii) conflict with in any material respect, result in a material breach of, constitute
a material default under, result in the acceleration of any right under, create in any party the right to accelerate, terminate,
modify or cancel, give rise to a material payment obligation under, require any notice, consent or waiver under, or result in the
loss of any material benefit to which AVRA is entitled under, any material contract to which AVRA is a party or by which AVRA is
bound, (iii) result in the creation or imposition of any Lien upon any of AVRA's assets, or (iv) violate in any material respect
any Laws applicable to AVRA or any of its properties or assets. No consent, notice, waiver, approval, order or authorization of
any governmental entities required by AVRA in connection with the execution and delivery of this Agreement. 

 

    	-8-

    	 

    

 

		3.5.	Financial Statements. AVRA will make available to HeartWare the following documents, all
of which are available on the EDGAR database of the Securities of Exchange Commission for companies reporting under the Securities
Exchange Act of 1934: (i) the [2011Audited Balance Sheet] of AVRA, together with all notes thereto; (ii) an unaudited balance sheet
of AVRA as of June 30, 2012 (the "Balance Sheet Date"); which are collectively referred to herein as the "Financial
Statements." Except as disclosed in the Financial Statements or on Section 3.5of the Disclosure Schedule, the Financial Statements
have been prepared in accordance with the books and records of AVRA and generally accepted accounting principles,
consistently applied throughout the periods involved ("GAAP") and fairly present, in all material respects, the financial
condition and results of operations of AVRA and its Subsidiary, on a consolidated basis, as of the respective dates thereof and
for the respective periods covered thereby. Except as set forth in the Financial Statements, AVRA has no material liabilities or
obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to the
Balance Sheet Date, (ii) obligations under contracts and commitments incurred in the ordinary course of business, and (iii)
liabilities and obligations of a type or nature not required under GAAP to be reflected in the Financial Statements, which, in
all such cases, individually and in the aggregate would not have a material adverse effect on the business of AVRA. 

 

    	-9-

    	 

    

 

		3.6	Litigation. There is no litigation, action, suit, proceeding, inquiry, claim, arbitration
or investigation pending or, to the knowledge of AVRA, threatened (a) against AVRA, the Subsidiaries or any of their assets or
property or any of their directors or officers in their capacities as such or (b) relating to, affecting or arising
in connection with this Agreement, or the transactions contemplated hereunder or thereunder. Neither AVRA nor the Subsidiaries
is party to or subject to, nor are any assets of AVRA or the Affiliates subject to, the provisions of any Court Order or any settlement
or similar agreement or written arrangement with ongoing obligations relating to a dispute (or the resolution of a dispute) with
any Person. 

 

		3.7.	Rights of Registration and Voting Rights. Neither AVRA nor the Subsidiaries are under any
current obligation to register under the Securities Act of 1933 any of its currently outstanding securities or any securities issuable
upon exercise or conversion of its currently outstanding securities. No stockholder of AVRA has entered into any agreements with
respect to the voting of capital shares of AVRA. AVRA is a reporting company under the Securities Exchange Act of 1934 (the “Exchange
Act”) and intends to take such action under the Securities Act of 1933 and the Exchange Act to register its shares for issuance
and trading customary for a public company.

 

		3.8.	Taxes. There are no federal, state, county, local or foreign Taxes due and payable by AVRA
or the Subsidiaries which have not been timely paid when due. There are no accrued and unpaid federal, state, country, local or
foreign Taxes of AVRA or the Subsidiaries which are due, whether or not assessed or disputed. AVRA and the Subsidiaries have duly
and timely filed all federal, state, county, local and foreign Tax returns required to have been filed by it and there are in effect
no waivers of applicable statutes of limitations with respect to Taxes for any year.

    	-10-

    	 

    

 

		3.9.	Insurance. AVRA intends to have in full force and effect directors and officers’ insurance
policies with extended coverage within thirty days of the date of this Agreement. In AVRA’s opinion, the coverage will be
sufficient in amount (subject to reasonable deductions) to defend and indemnify its directors and officers for actions taken on
behalf of AVRA or the Subsidiaries.

 

		3.10.	Employee Agreements. Each current and former employee, consultant and officer of AVRA and
the Subsidiaries have executed an agreement with AVRA or the Subsidiaries, as applicable, regarding confidentiality, proprietary
information and assignment of inventions (the "Confidential Information Agreements"). .

 

		3.10.	Intellectual Property. Control of AVRA was recently acquired by Granite Investor Group,
Inc., a Delaware corporation, and was converted from a reporting shell company to an operating company in the business of designing,
developing, manufacturing and marketing robotics for medical and other applications. AVRA is in the process of acquiring, directly
or through subsidiaries, Company Intellectual Property. With respect to such Company Intellectual Property that AVRA presently
owns:

 

		(a)	Neither AVRA nor the Subsidiaries is in breach of, and each has complied in all material respects
with, all terms of, any license, agreement or other contract relating to Company Intellectual Property. Neither AVRA nor the Subsidiaries
has received any notice of breach of any license or other agreement relating to Company Intellectual Property. To the extent Patents
are sublicensed to AVRA or the Subsidiaries by a third Person, AVRA's or the Subsidiaries' sublicensed rights continue in full
force and effect if the principal third Person license terminates for any reason.

 

    	-11-

    	 

    

 

		(b)	AVRA or the Subsidiaries
exclusively or non-exclusively, as the case may be, owns or licenses all right, title and interest to and under Company Intellectual
Property identified on the Disclosure Schedule, free and clear of any Liens, except Permitted Liens. All documents and instruments
necessary to perfect the ownership rights of AVRA or the Subsidiaries in Company Intellectual Property identified on the Disclosure
Schedule have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority. AVRA and
the Subsidiaries have taken all commercially reasonable steps in accordance with normal industry practice to maintain the confidentiality
of and otherwise protect and enforce their respective rights in all proprietary information that AVRA and the Subsidiaries hold,
or purport to hold, as a trade secret, and AVRA and the Subsidiaries have good title to and an absolute right to use the trade
secrets included in the Company Intellectual Property. 

 

		(c)	AVRA or the Subsidiaries have Intellectual Property
rights sufficient for it to conduct its current business activities. To the
best of its knowledge, neither AVRA nor the Subsidiaries have infringed, misappropriated or otherwise violated any Intellectual
Property right of any other Person, and neither AVRA nor the Subsidiaries has received any claims nor are any claims threatened
or, to the best of its knowledge, do valid grounds exist for any such claim. 

 

    	-12-

    	 

    

 

		3.12.	Compliance with Laws and Regulatory Matters. AVRA has complied, in all material respects, with
all Laws and guidance (including, without limitation, current governmental regulations concerning good laboratory practices, good
clinical practices and good manufacturing practices) applicable to the development activities for Company.

 

		3.13.	Advisors and Brokers. AVRA has not incurred
and will not incur, directly or indirectly, any investment banking or "finders" fees or any other fees related to business
or advisory services in connection with the transactions contemplated by this
Agreement. 

 

		3.14.	Disclosure. No representation or warranty of AVRA contained in this Agreement, as qualified
by the Disclosure Schedule, and no certificate furnished or to be furnished to HeartWare at the Closing contains any untrue statement
of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not
misleading in light of the circumstances under which they were made.

 

		Article 4.	Heart Ware's Representations and Warranties.

 

		4.1.	Organization; Authority. HeartWare is a corporation duly organized, validly existing and
in good standing under the Laws of the State of Delaware. HeartWare has the requisite corporate power and authority to carry on
its business as currently being conducted. HeartWare is not in violation of any provision of its certificate of incorporation or
bylaws

 

    	-13-

    	 

    

 

		4.2.	Conflicts. HeartWare's execution and delivery of this Agreement, and the consummation of
the transactions contemplated hereby and thereby, does not and will not (i) conflict with or violate any provision of its certificate
of incorporation or bylaw, (ii) conflict with in any material respect, result in a material breach of, constitute a material default
under, result in the acceleration of any right under, create in any party the right to accelerate, terminate, modify or cancel,
give rise to a material payment obligation under, require any notice, consent or waiver under, or result in the loss of any material
benefit to which HeartWare is entitled under, any material contract to which HeartWare is a party or by which HeartWare is bound,
(iii) result in the creation or imposition of any Lien upon any of HeartWare's assets, or (iv) violate in any material respect
any Laws applicable to HeartWare or any of its properties or assets. No consent, notice, waiver, approval, order or authorization
of any governmental entities required by HeartWare in connection with the execution and delivery of this Agreement.

 

		4.3.	Restricted Securities.  HeartWare is purchasing the HeartWare Shares for its own account
as an investment, and has no present plan to sell or transfer any of the shares. HeartWare understands that neither this Agreement
nor any of the material to which HeartWare has had access in connection with the entry into this Agreement has been filed with
or reviewed by the Securities and Exchange Commission or with the Attorney General, Securities Commissioner or comparable regulatory
authority of any state.

 

    	-14-

    	 

    

 

		4.4.	Accredited Investor. HeartWare has been granted the opportunity to ask questions of representatives
of AVRA concerning the terms and conditions of this investment and AVRA's present and proposed businesses. HeartWare understands
that the shares to be issued pursuant to this Agreement are offered and sold to HeartWare
under the exemption from registration available for private offerings under Section 4(2) of the Securities Act of 1933, as amended.
HeartWare represents that it is purchasing the Common Stock and the Warrant for investment and not with a view to any public distribution
thereof. HeartWare is an "Accredited Investor" as that term is defined in Regulation D promulgated by the Securities
and Exchange Commission. 

 

		4.5.	Advisors and Brokers. HeartWare has not incurred and will not incur, directly or indirectly,
any investment banking or "finders" fees or any other fees related to business or advisory services in connection with
the transactions contemplated by this Agreement.

 

		Article 5.	Confidentiality Agreement.

 

		5.1.	Attached as Exhibit D is a copy of the parties' Non-Disclosure Agreements dated August 10, 2012.
The parties incorporate by reference the terms of the Non-Disclosure Agreement as if fully set forth herein.

 

		Article 6.	Dispute Resolution

 

		6.1.	The Parties recognize that disputes as to certain matters may from time to time arise that relate
to the Parties' rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the
resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation.
To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 6 to resolve any controversy
or claim arising out of, relating to or in connection with any provision of this Agreement, if and when a dispute arises under
this Agreement. 

 

    	-15-

    	 

    

 

		6.2.	With respect to all disputes arising between the Parties in under this Agreement, including any
alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties
are unable to resolve the dispute within thirty (30) days after the dispute is first identified by either Party in writing to the
other, the Parties shall refer the dispute to the executive officers of the Parties for attempted resolution by good faith negotiations
within thirty (30) days after such notice is received, including at least one (1) in-person meeting of the executive officers within
twenty (20) days after notice is received.

 

		6.3.	If the executive officers of the Parties are not able to resolve any dispute referred to them under
Section 6.2 within such thirty (30) day period, then each Party shall have right to pursue any legal or equitable remedy available
to it under applicable Laws, provided that any litigation arising under this Agreement shall be brought in a state or federal court
located in State of Delaware. Each Party hereby agrees to the exclusive jurisdiction of such courts and waives any objections as
to the personal jurisdiction or venue of such courts.

    	-16-

    	 

    

 

		Article 7.	Miscellaneous.

 

		7.1.	This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement
and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto
with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings between the
Parties with respect to the subject matter hereof, excluding the Non-Disclosure Agreement. The foregoing shall not be interpreted
as a waiver of any remedies available to either Party as a result of any breach, prior to the date hereof, by the other Party of
its obligations under the Non-Disclosure Agreement. There are no covenants, promises, agreements, warranties, representations,
conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed
by an authorized officer of each Party.

 

		7.2.	Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically
refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as
may be specified by such Party in writing in accordance with this Section 8.2, and shall be deemed to have been given for all purposes
(a) when received, if hand-delivered or when sent, if by confirmed facsimile or a pdf document sent by confirmed email, or a reputable
overnight courier service, or (b) five (5) business days after mailing, if mailed
by first class certified or registered mail, postage prepaid, return receipt requested. 

    	-17-

    	 

    

 

	If to AVRA:	
        Barry F. Cohen, Chairman

        AVRA Surgical, Inc.

        1209 Orange Street

        Wilmington, Delaware 19801

        Fax:      302-655-5049

	 	 
	With a copy to:	
        Jared B. Stamell, Esq.

        Stamell & Schager, LLP

        One Liberty Plaza, 35th Floor

        New York, New York 10006-1404

        Fax:      212-566-4061

	 	 
	If to HeartWare:	
        HeartWare, Inc.

        205 Newbury Street

        Framingham, Massachusetts 01701

        Attn: Chief Executive Officer

        Fax:      508-739-0948

	 	 
	With a copy to:	
        HeartWare, Inc.

        205 Newbury Street

        Framingham, Massachusetts 01701

        Attn: General Counsel

        Fax:      508-739-0948

 

		7.3.	This Agreement has been prepared jointly by the Parties and shall not be strictly construed against
either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may
be deemed to have authored the ambiguous provision. Any headings in this Agreement have been inserted for convenience of reference
only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. Except
where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word "or" is
used in the inclusive sense (and/or). The term "including" as used herein means including, without limiting the generality
of any description preceding such term. 

 

    	-18-

    	 

    

 

		7.4.	The terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

 

		7.5.	Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement. 

 

		7.6.	If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by
any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this
Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when
entering this Agreement may be realized.

 

		7.7.	Any delay in enforcing a Party's rights under this Agreement or any waiver as to a particular default
or other matter shall not constitute a waiver of such Party's rights to the future enforcement of its rights under this Agreement,
except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.

    	-19-

    	 

    

 

		7.8.	Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be
construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall
be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.

 

		7.9.	This Agreement was prepared in the English language, which language shall govern the interpretation
of, and any dispute regarding, the terms of this Agreement. This Agreement and all disputes arising out of or related to this Agreement
or any breach hereof shall be governed by and construed under the Laws of the State of Delaware, without giving effect to any choice
of law principles that would require the application of the laws of a different state.

 

		7.10.	This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.

 

[Signatures Appear on Following
Page]

 

    	-20-

    	 

    

 

IN WITNESS WHEREOF, the Parties have executed
this Agreement by their duly authorized officers as of the date first written above.

 

	HEARTWARE, INC.	 	AVRA SURGICAL ROBOTICS, INC.
	 	 	 	 
	By:	/s/ Doug Godshall	 	By	/s/ Jared B.
Stamell
		 	 	 	 
	Name:	Doug Godshall	 	Name	JARED B. STAMELL
	 	 	 	 	 
	Title:	President/CEO	 	Title	VICE PRESIDENT &  GENERAL COUNSEL

  

    	-21-

    	 

    

 

Exhibits: 

 

	 	Exhibit A:	Disclosure Schedule
	 	 	 
	 	Exhibit B:	AVRA Certificate of Incorporation
	 	 	 
	 	Exhibit C:	AVRA Bylaws 
	 	 	 
	 	Exhibit D:	Non-Disclosure Agreements dated August 10, 2010

 

    	-22-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]